Summary of EXELIXIS, INC. - Yahoo! Finance

Change in Directors or Principal Officers, Financial Statements and Exhibits

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On December 4, 2012, the Board of Directors (the "Board") of Exelixis, Inc. (the "Company" or "Exelixis"), upon recommendation of the Compensation Committee of the Board, approved a special company-wide one-time cash bonus for the Company's employees, including the Company's named executive officers, in recognition of their efforts in connection with the approval of COMETRIQ™ (cabozantinib) by the U.S. Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer in the United States. COMETRIQ is the first Exelixis compound to have been discovered and developed through marketing approval. The special one-time cash bonus payments will be made to the Company's employees, including the named executive officers, in December 2012.

The special one-time cash bonus payments to each of the Company's named executive officers are listed in Exhibit 10.1 attached hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number       Description

10.1         Special One-Time Cash Bonus Information for the Company's Named
             Executive Officers